What is HC Wainwright’s Forecast for MediWound Q3 Earnings?

MediWound Ltd. (NASDAQ:MDWD) – Equities research analysts at HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for shares of MediWound in a report issued on Friday, August 14th. HC Wainwright analyst S. Ramakanth now forecasts that the biopharmaceutical company will earn ($0.62) per share for the quarter, down from their prior forecast of ($0.49). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.31) per share. HC Wainwright also issued estimates for MediWound’s Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($2.02) EPS, Q1 2027 earnings at ($0.55) EPS, Q2 2027 earnings at ($0.57) EPS, Q3 2027 earnings at ($0.47) EPS, Q4 2027 earnings at ($0.42) EPS, FY2027 earnings at ($2.00) EPS, FY2028 earnings at ($0.98) EPS, FY2029 earnings at $0.75 EPS and FY2030 earnings at $2.25 EPS.

MediWound (NASDAQ:MDWD) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01). The firm had revenue of $3.09 million for the quarter, compared to analyst estimates of $2.59 million. MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%.

Other equities analysts have also issued research reports about the stock. Oppenheimer reiterated an “outperform” rating and issued a $30.00 price objective (down from $32.00) on shares of MediWound in a report on Friday. Wall Street Zen lowered MediWound from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of MediWound in a research note on Friday, July 17th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $33.00.

MediWound Trading Down 1.3%

MDWD opened at $13.39 on Tuesday. The company has a fifty day simple moving average of $14.33 and a 200 day simple moving average of $15.92. The firm has a market cap of $172.06 million, a price-to-earnings ratio of -7.44 and a beta of 0.15. MediWound has a twelve month low of $13.29 and a twelve month high of $20.30.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of MDWD. Silverberg Bernstein Capital Management LLC boosted its position in MediWound by 8.7% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 200,005 shares of the biopharmaceutical company’s stock worth $3,222,000 after acquiring an additional 16,081 shares during the period. Sphera Funds Management LTD. increased its holdings in shares of MediWound by 24.3% in the 4th quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company’s stock valued at $4,252,000 after purchasing an additional 45,077 shares during the period. Kotler Kevin acquired a new position in shares of MediWound in the 4th quarter valued at about $6,225,000. Russell Investments Group Ltd. lifted its position in shares of MediWound by 45.1% in the fourth quarter. Russell Investments Group Ltd. now owns 3,653 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 1,135 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of MediWound during the fourth quarter worth approximately $297,000. 46.83% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director David Morton Fox bought 3,537 shares of the business’s stock in a transaction on Monday, June 1st. The shares were bought at an average cost of $14.11 per share, with a total value of $49,907.07. Following the purchase, the director directly owned 22,283 shares in the company, valued at $314,413.13. This trade represents a 18.87% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 9.20% of the company’s stock.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.